Compare Dyne Therapeutics Inc. Common Stock (DYN) vs NXP Semiconductors N.V. Common Stock (NXPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs NXP Semiconductors N.V. Common Stock — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while NXP Semiconductors N.V. Common Stock trades at $218.68 (market cap $57.07B). The key difference: NXP Semiconductors N.V. Common Stock is far larger — about 20× Dyne Therapeutics Inc. Common Stock's market cap, and NXP Semiconductors N.V. Common Stock pays a 1.79% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and NXP Semiconductors N.V. Common Stock for 5 Days on average.
| DYN | NXPI | |
|---|---|---|
Market Cap | $2.86B | $57.07B |
Volume | 3,341,579 | 3,033,835 |
Sector | Health | Technology |
52-Week High | $26.78 | $332.67 |
52-Week Low | $14.60 | $184.19 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $2.18B | $65.18B |
Dividend Yield | — | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
NXP Semiconductors (NXPI) trades at $226.32, up 0.49% with a bearish technical signal despite strong fundamentals. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue grew to $12.27B in 2025 with a robust 22.56% net margin, while analysts maintain a 65% buy rating with a $282.88 consensus target. Recent news highlights executive stock sales and focus on physical AI leadership.
NXPI offers growth potential driven by earnings beats and strategic positioning in semiconductors, but faces near-term technical pressure and competitive risks. The stock trades below analyst targets, suggesting upside if fundamentals hold. Key risks include market volatility and execution challenges in a cyclical industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About NXP Semiconductors N.V. Common Stock
NXP Semiconductors designs semiconductor solutions for embedded applications. Its products serve automotive, industrial and IoT, mobile, and communications-infrastructure markets.
Read more on NXPI →
